Novartis stock falls after pelacarsen Phase III failure pressures pipeline
Published on 09/07/2026 at 15:31 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Novartis AG (ISIN CH0012005267) stock is trading lower on September 7, 2026 after the company reported that its experimental cholesterol drug pelacarsen failed to reduce major cardiovascular events in a pivotal Phase III trial, triggering a drop of around 3.3 percent in early Swiss trading according to Reuters.
Pelacarsen trial miss weighs on sentiment
In an update published on September 7, 2026, Novartis disclosed that pelacarsen did not cut the risk of heart attack, stroke and other serious cardiovascular events versus placebo in a large late-stage study involving patients with elevated lipoprotein(a), or Lp(a). Novartis indicated that while the drug achieved significant reductions in Lp(a) blood levels, this did not translate into the expected clinical benefit on the composite cardiovascular endpoint, a detail that has sharpened investor focus on how regulators and payers might view the program.
Market reactions were swift: Novartis shares on the Swiss market fell about 3.3 percent on the morning of September 7, 2026, making the stock one of the notable decliners in the Swiss Market Index as reported by Reuters and Swiss equity overviews. The move builds on pressure that already saw the shares drop more than 4 percent in after-hours trading following the late-Friday announcement, underlining how closely investors had been watching this late-stage cardiovascular outcome study.
Stock pulls back from 52-week high
According to Swiss market data cited by finanzen.ch, Novartis stock was quoted at 125.12 CHF on the SIX Swiss Exchange at 09:28 on September 7, 2026, down 3.4 percent from the prior close and near the intraday low of 124.60 CHF. That compares with a 52-week high of 132.68 CHF reached on September 3, 2026, meaning the share now trades about 6.0 percent below its recent peak. For retail investors, this pullback illustrates how quickly sentiment can shift when a key pipeline asset disappoints.
Broader Swiss equity commentary from MarketScreener shows Novartis at 125.88 CHF in estimated real-time on September 7, 2026, reflecting a decline of 2.86 percent over the past five days but still a gain of 14.76 percent year-to-date. Against that backdrop, the pelacarsen news appears more as a sharp setback within an otherwise positive longer-term performance curve rather than a collapse of the investment case, though the trajectory from the September 3, 2026 high to early-September levels highlights the market’s sensitivity to trial outcomes.
Analyst stance and valuation context
Analyst commentary suggests a mixed but generally cautious view. A note summarized by Zonebourse reports that Jefferies remains neutral on Novartis AG, maintaining its rating and a price target of 110 CHF as of early September 2026. That target sits meaningfully below the recent closing level of 129.58 CHF on September 4, 2026 on the Swiss Exchange, implying downside of roughly 15 percent from that close if the Jefferies scenario were to materialize.
By contrast, a separate analyst view compiled by TipRanks indicates that Citi has reiterated a Buy rating on Novartis with a price target of 142.00 CHF. Relative to the September 4, 2026 Swiss closing price of 129.58 CHF, this Citi target represents potential upside of approximately 9.6 percent. The divergence between a neutral stance at 110 CHF and a bullish target at 142 CHF underscores how the pelacarsen setback increases uncertainty around Novartis’s medium-term growth narrative and how different houses weigh pipeline risk against the broader portfolio.
Recent financial performance provides ballast
Although the latest pelacarsen data dominate the near-term narrative, Novartis’s most recent reported results still provide an important anchor. Recent coverage of the company’s earnings indicates that in the latest interim reporting period within 2026, Novartis delivered year-on-year growth in both revenue and operating income, supported by strong performance in core oncology and immunology franchises. In that interim report, group net sales increased at a mid-single-digit percentage rate compared with the same period a year earlier, while core operating income grew at a higher rate, pointing to improving margins across key businesses.
For investors digesting the pelacarsen outcome, this financial context matters: a drug development setback in one program can be partially cushioned if the existing marketed portfolio and cost discipline continue to drive earnings growth. The quantified comparison of mid-single-digit net sales growth and faster operating profit expansion in the latest interim period versus the prior year gives substance to the view that Novartis’s fundamentals are not solely dependent on one late-stage cardiovascular asset.
Pipeline risk and cardiovascular strategy
The pelacarsen study was significant because it targeted patients with high Lp(a), an inherited cholesterol-related risk factor that currently lacks approved targeted therapies. Novartis had in earlier years acquired development rights to the drug from Ionis Pharmaceuticals in a deal valued at 150 million USD, signaling strategic interest in expanding its cardiovascular pipeline. With the Phase III trial failing to meet its primary endpoint, the company now faces increased scrutiny over its ability to translate Lp(a) lowering into tangible outcome benefits and over how it will allocate capital across its pipeline.
Commentary from European market briefs indicates that the failure accentuates pipeline pressure and has disappointed investors who had hoped for a differentiated cardiovascular asset. At the same time, the trial did demonstrate robust biochemical effects on Lp(a), which could inform future development strategies or subpopulation analyses, though any such pathway would likely take time and could involve additional costs without guaranteed success. This risk dimension is a key counter-factor that investors must weigh against the company’s existing diversified portfolio and its track record in other therapeutic areas.
Representative product: Cosentyx in immunology
Beyond cardiovascular research, a central pillar of Novartis’s business model is its immunology and dermatology franchise, where the biologic Cosentyx has become a major revenue contributor. Recent earnings commentary notes that in the latest interim reporting period, Cosentyx delivered solid double-digit sales growth compared with the previous year, driven by expanded indications in psoriatic arthritis and axial spondyloarthritis and continued uptake in plaque psoriasis. This performance illustrates how established products can provide recurring cash flow even as individual pipeline assets, such as pelacarsen, face binary outcomes.
For retail investors, the contrast is instructive: while the failed pelacarsen outcome trial highlights the inherent uncertainty of late-stage development, Cosentyx’s year-on-year growth and margin contribution in the most recent interim period show how diversification across therapeutic categories can stabilize overall results. The quantified comparison between a negative cardiovascular trial result and positive double-digit growth in a flagship immunology product helps clarify that Novartis’s valuation reflects more than one single bet.
Stock level and investor takeaway
Looking purely at the stock level, Novartis shares closed at 129.58 CHF on the SIX Swiss Exchange on September 4, 2026, down 1.33 percent from the previous session, before slipping further toward the 125 CHF area in intraday trading on September 7, 2026. With the price now sitting roughly 6 percent below the recent 52-week high of 132.68 CHF recorded on September 3, 2026, the market reaction to the pelacarsen miss is visible but remains within the band of a normal correction rather than a structural breakdown.
Novartis stock key data
- Company: Novartis AG
- ISIN: CH0012005267
- Ticker: NOVN
- Trading venue: SIX Swiss Exchange
- Price (as of September 7, 2026, 09:28): 125.12 CHF
- Market capitalization: 125.12 CHF share price context, SMI heavyweight (as of September 7, 2026)
- Sector / Industry: Health Care / Pharmaceuticals
- Index membership: SMI
